NasdaqGS:EXELBiotechs
Assessing Exelixis (EXEL) Valuation After Analysts Lift 2026 Earnings Forecasts
Exelixis (EXEL) is back on investor radars after six analysts raised their earnings forecasts for fiscal 2026, citing the company’s oncology pipeline and their growth expectations as key reasons for the revised outlook.
See our latest analysis for Exelixis.
Even with the recent analyst optimism, Exelixis’ shares have cooled slightly, with a 30 day share price return of a 4.21% decline and a year to date share price return of a 5.53% decline. At the same time, the 1 year total shareholder...